Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of generic pharmaceuticals, primarily targeting the Chinese market. The company has a competitive edge in its extensive product portfolio, which includes over 100 varieties of medicines, particularly in the fields of cardiovascular and anti-infective treatments.
Hunan Jingfeng generates revenue through the sale of generic drugs, which are priced competitively compared to branded alternatives, allowing for significant market penetration. The company benefits from low production costs due to its efficient manufacturing processes and a strong distribution network across China.
Regulatory approvals for new drug formulations
Changes in government healthcare policies impacting drug pricing
Market share shifts in the generic pharmaceuticals sector
Innovation in drug development processes
Regulatory changes affecting drug approval processes
Technological disruption in drug manufacturing
Intense competition from other generic drug manufacturers
Potential price erosion due to market saturation
Negative net income impacting liquidity
High operating losses leading to potential cash flow issues
moderate - The company's performance is somewhat linked to GDP growth, as increased consumer spending can lead to higher pharmaceutical sales.
Low - The company has no debt, so rising interest rates do not affect financing costs, but they may impact consumer spending on healthcare.
minimal - The company operates without debt, reducing exposure to credit conditions.
value - Investors may be drawn to the stock due to its low valuation metrics despite recent performance challenges.
high - The stock has shown significant price fluctuations, reflecting operational instability.
